Macquarie analyst Frederick Havemeyer initiates coverage on CrowdStrike Holdings (NASDAQ:CRWD) with a Outperform rating and announces Price Target of $220.
Cidara Therapeutics Granted U.S. Patent #11524980: Synthesis of echinocandin antifungal agent
https://www.scribd.com/document/614190266/CDTX-Patent